Breaking India State Business Entertainment Biography Lifestyle

127 crores to hit Namita Thapar’s account in one fell swoop, this is the beauty with brains marvel.

Sagar Patel

By Sagar Patel

Published on:

127 Crores Will Hit Namita Thapar’s Account In One Go, This Will Be Amazing

Shark Tank judge Namita Thapar is a perfect example of beauty with brains. We say this because apart from being a successful entrepreneur, she is also a very smart investor. Actually, Emcure Pharmaceuticals IPO will open on July 3 and bids can be placed till July 5. A lucky draw will be conducted through this IPO of Namita Thapar, part of the promoter group and of Shark Tank fame. Rs 127 crore will soon come to her account through this IPO. Let us know how…

This will do wonders.

Actually, Namita Thapar had bought shares of Amcure at an average price of Rs 3.44 per share. She will sell around 12.68 lakh shares under OFS in this IPO. Considering the upper price band of Rs 1,008, they will get around Rs 127 crore from this stake sale. As of March 2024, Thapar holds around 63 lakh shares or 3.5% stake in the company. New shares worth Rs 800 crore will be issued in this IPO. Promoters and existing shareholders will sell 1.14 crore equity shares through OFS.

These promoters are included.

Others who sold their stake under the SFO include promoter Satish Mehta and investor BC Investments IV Ltd, linked to US private equity firm Bain Capital. The company says the proceeds from this issuance will be used for debt repayment and general corporate purposes. Pune-based company Emcure Pharma is engaged in the development, manufacturing and marketing of many medicines. Based on R&D, this company has many types of products. Its business is spread in more than 70 countries.

How much can you invest?

At least 14 shares can be purchased in one lot. If we look at the price band, you will have to invest at least ₹14,112 in this IPO. While sNII will have to invest at least 15 lots i.e. Rs 211,680. While bNII will have to invest ₹1,001,952 for 71 lots.

So much profit can be made

Even before the IPO opens, this company is already reporting good profits in the grey market. Its GMP is considered to be Rs 300 per share. That means that the shares of this company can trade around Rs 1,300, which is 29 percent higher than the price band.

What work does the company do?

Established in 1981, Emcure Pharmaceuticals is an Indian pharmaceutical company that develops, manufactures and globally markets a wide range of pharmaceutical products across several key therapeutic areas. Emcure Pharmaceuticals has 13 manufacturing facilities in India. Emcure Pharma reported a net profit of Rs 527.58 crore on revenue of Rs 6,715.24 crore for the financial year ended March 31, 2024. The company’s net profit for the financial year 2022-23 stood at Rs 561.85 crore on revenue of Rs 6,031.72 crore.

Sagar Patel

Sagar Patel

I am Sagar Patel, specializing in business news reporting. With a keen focus on economic trends, market analysis, and corporate developments,

Related Post

Leave a comment